Collas Crill advised in a private equity deal for Asclepios
Bioresearch and in particular assisted with the funding and
security structure of the deal.
Asclepios Bioresearch (UK) Limited provided
£20,000,000 of funding to develop B-hydroxybutyrate on behalf of
Iceland Foods Limited.
The deal is considered an important milestone in the
fight against Alzheimer's Disease. Asclepios Bioresearch's
scientific committee is particularly excited about the patent's
potential against such a debilitating ailment. The testing process
is now proceeding and Asclepios Bioresearch's contract research
organisation is in active discussions with a pharmaceutical
company, who are formulating B-hydroxybutyrate for patient
Also involved in the transaction were Hoiberg A/S
(Copenhagen), Jeffery Green Russell (London), Crestgrove Limited,
Grant Thornton UK LLP and SWG Services Limited.